Navigation Links
UPM Pharmaceuticals Enhances its Pre-Formulation Capabilities

Baltimore, MD (PRWEB) January 09, 2013

UPM Pharmaceuticals announced today that it has purchased and qualified a TA Instruments Q20 Auto MDSC (Differential Scanning Calorimeter), and a TA Instruments Q50 TGA (Thermogravimetric Analyzer). These pieces of equipment greatly enhance the formulation development company’s ability to provide comprehensive pre-formulation studies, as well as support analytical testing of challenging formulations such as poorly soluble compounds.

UPM’s President, Jim Gregory, said, “UPM sees these new pieces of analytical equipment combined with our already highly qualified and experienced analytical team as a powerful combination for our clients who are trying to make the best and most cost effective decisions about investment of precious research funds. And further is looking for a partner that can perform the latest and best analysis with the most reliable equipment available in the pre-formulation stage of development.”

UPM Pharmaceuticals®, Inc. is a Baltimore-based contract development and manufacturing organization providing customized formulation development, manufacturing, and analytical services to pharmaceutical, biotechnology, academic, and veterinary clients.

Fully appreciating that time-to-market is critical, UPM offers remarkably flexible, affordable, and rapid outsourcing services designed to meet clients’ specific development and manufacturing needs. Their clients represent both small and large companies within the pharmaceutical and biotechnology industries, and academic institutions who have a focus on clinical studies.

About UPM Pharmaceuticals

UPM Pharmaceuticals, Inc. is a Baltimore-based, independent drug development and contract manufacturer serving the pharmaceutical and biotechnology industries. They provide high quality pharmaceutical drug development services including formulation development, cGMP manufacturing, analytical methods development and stability testing. They are characterized by the quality, speed and thoroughness with which they complete all their projects. UPM’s clients enjoy service that is customized and fast with total quality management characteristic of a customer-focused business. Their history includes successful collaborative interactions with virtual to multi-million dollar companies providing them with customized product development services and solutions. UPM focuses on drug development for dosages with oral routes of administration, in solid dosage forms such as capsules and tablets.

To learn more about UPM, please visit the Web site at

UPM Pharmaceuticals is a registered U.S. trademark.

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Biosim Pharmaceuticals, Manufacturers of Generic ACTHAR, to Participate at Biotech Showcase 2013
2. Rafarma Pharmaceuticals, Inc. Achieves Full Certification
3. Auxilium Pharmaceuticals, Inc. to Present At The Oppenheimer 23rd Annual Growth Conference
4. Inovio Pharmaceuticals Announces Positive Interim Results in Phase II Leukemia Trial
5. Gallus BioPharmaceuticals Announces Appointment of Senior Baxter Executive as Chief Commercial Officer
6. Ampio Pharmaceuticals, Inc. (AMPE) announces appointment of Josh Disbrow as Chief Operating Officer effective December 15, 2012
7. Inovio Pharmaceuticals Cytomegalovirus (CMV) Synthetic Vaccine Constructs Generate Strong and Broad T-Cell Responses in Preclinical Study
8. OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Update and Reports Financial Results for Third Quarter 2012
9. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2012 Financial Results
10. Vanda Pharmaceuticals to Present at the Lazard Healthcare Conference
11. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess of $100,000 Investing In Keryx Biopharmaceuticals, Inc. To Contact the Firm
Post Your Comments:
(Date:11/25/2015)... , Nov. 25, 2015  Neurocrine Biosciences, Inc. (Nasdaq: ... , President and CEO of Neurocrine Biosciences, will be ... in New York . ... the website approximately 5 minutes prior to the presentation ... of the presentation will be available on the website ...
(Date:11/25/2015)... ... November 25, 2015 , ... Jessica Richman and Zachary Apte, ... their initial angel funding process. Now, they are paying it forward to other ... stage investments in the microbiome space. In this, they join other successful ...
(Date:11/24/2015)... 24, 2015 /CNW/ - iCo Therapeutics ("iCo" or "the ... results for the quarter ended September 30, 2015. ... dollars and presented under International Financial Reporting Standards ... ," said Andrew Rae , President & ... are not only value enriching for this clinical ...
(Date:11/24/2015)... November 24, 2015 --> ... research report "Oligonucleotide Synthesis Market by Product & Services ... Synthesis, Diagnostic, DNA, RNAi), End-User (Research, Pharmaceutical & Biotech, ... MarketsandMarkets, the market is expected to reach USD 1,918.6 ... at a CAGR of 10.1% during the forecast period. ...
Breaking Biology Technology:
(Date:10/27/2015)... Munich, Germany , ... (ASGM) automatically maps data from mobile eye tracking videos ... so that they can be quantitatively analyzed with SMI,s ... Germany , October 28-29, 2015. SMI,s Automated Semantic ... eye tracking videos created with SMI,s Eye Tracking ...
(Date:10/26/2015)... and LAS VEGAS , Oct. 26, ... , an innovator in modern authentication and a founding ... the launch of its latest version of the Nok ... organizations to use standards-based authentication that supports existing and ... Authentication Suite is ideal for organizations deploying customer-facing applications ...
(Date:10/23/2015)... BERLIN and GOLETA, California ... the HFES conference, BIOPAC and SensoMotoric Instruments (SMI) announce ... and eye tracking data captured during interactive real-world tasks ... plug and play integration of their established wearable solutions ... researchers to synchronize gaze behavior captured with SMI ...
Breaking Biology News(10 mins):